As a globally operating, independent biosimilar developer, Formycon actively contributes to improving patients' access to high-quality, safe and affordable biologic medicines.
Our sustainability strategy describes how we intend to strengthen the positive impact of our business activities, minimize negative impacts and effectively mitigate sustainability-related risks.
You are currently viewing a placeholder content from Vimeo. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
You are currently viewing a placeholder content from YouTube. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
